Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Understanding Your Diagnosis: AIDP and GBS

At a Glance

AIDP is the most common form of Guillain-Barré Syndrome (GBS). It occurs when the immune system attacks the nerve's myelin coating, causing rapidly progressing weakness. Symptoms typically peak within four weeks, and treatments like IVIG or plasma exchange offer a favorable long-term prognosis.

It is completely normal to feel overwhelmed or even panicked right now. Hearing a complex name like Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) while experiencing sudden weakness or paralysis is a frightening experience [1][2].

However, you should know that you are not alone, and your care team is working with a well-understood condition. AIDP is the most common form of Guillain-Barré Syndrome (GBS) in North America and Europe [2][1]. While the symptoms are intense, there are established protocols to manage this condition and support your recovery.

Understanding the Biological Mechanism

In a healthy body, your nerves are covered by a protective coating called myelin, which acts like the insulation on an electrical wire. This insulation allows signals from your brain to travel quickly to your muscles.

In AIDP, your immune system—which usually fights off germs—becomes confused and begins to attack this myelin coating [1][2]. This process is called demyelination. When the insulation is damaged, the electrical signals to your muscles become slow or blocked, leading to the tingling, numbness, and weakness you are feeling [3][2].

Speed of Progression: What to Expect

AIDP is known for moving quickly, which is often the most distressing part for patients and families.

  • The Onset: Weakness often begins in the feet and legs and moves upward (“ascending”) [4].
  • The Nadir: This is the medical term for the “low point” or the peak of the symptoms. Most people reach their maximum level of weakness within four weeks of the first symptom appearing [5][6].
  • Stabilization: Once you reach the nadir, the progression stops. At this point, the body can begin the slow process of repairing the myelin and restoring strength [7][5].

Three Stabilizing Facts

If you find yourself spiraling into “what ifs,” keep these three facts in mind:

  1. The Mechanism is Well-Understood: Doctors know exactly why this is happening. It is an immune-mediated attack on the peripheral nerves, and they have clear diagnostic tools—like nerve conduction studies and spinal taps—to confirm it [1][2][8].
  2. Effective Treatments Exist: There are two primary “first-line” treatments designed to stop the immune system’s attack: Intravenous Immunoglobulin (IVIG) and Plasma Exchange (PLEX) [9][10]. Both are proven to be effective in helping patients recover faster [11][12].
  3. Prognosis is Generally Favorable: While the road to recovery requires patience and often involves physical therapy, the majority of people with AIDP have a favorable long-term outcome [13][14]. AIDP generally has a better prognosis than some of the rarer, “axonal” forms of GBS [13][15].

Your primary job right now is to communicate any new symptoms to your medical team—especially if you have any trouble breathing or swallowing—and to allow the treatments to begin their work [4][16].

(See the Home Page to view the full index)

Common questions in this guide

What is the difference between AIDP and Guillain-Barré Syndrome?
AIDP stands for Acute Inflammatory Demyelinating Polyradiculoneuropathy. It is not a separate disease, but rather the most common form or subtype of Guillain-Barré Syndrome found in North America and Europe.
What does reaching the 'nadir' mean in AIDP?
The nadir is the medical term for the lowest point or the peak severity of your symptoms. Most people with AIDP reach their maximum level of weakness within four weeks of their first symptom appearing.
Why does AIDP cause sudden tingling and weakness?
In AIDP, your immune system mistakenly attacks myelin, which is the protective coating around your nerves. When this insulation is damaged, electrical signals from your brain to your muscles are slowed down or blocked entirely.
How is AIDP treated?
The two primary first-line treatments for AIDP are Intravenous Immunoglobulin (IVIG) and Plasma Exchange (PLEX). Both therapies are highly effective at stopping the immune system's attack on your nerves so your body can begin repairing the damage.
Why is it so important to monitor my breathing with AIDP?
Because AIDP causes ascending weakness that starts in the legs and moves upward, it can eventually affect the muscles required for breathing and swallowing. Doctors monitor you closely to ensure these critical functions are not compromised during the active phase of the condition.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tests, is it confirmed that I have the AIDP subtype of GBS?
  2. 2.How do we know if I have reached the 'nadir' (the peak) of my symptoms?
  3. 3.What is the plan for monitoring my breathing and heart rate over the next few days?
  4. 4.Which treatment—IVIG or plasma exchange—do you recommend for my specific situation and why?
  5. 5.What are the expected milestones for my recovery in the coming weeks?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    [Target Molecule for a Demyelinating Type of Guillain-Barré Syndrome, Acute Inflammatory Demyelinating Polyneuropathy].

    Mori M

    Brain and nerve = Shinkei kenkyu no shinpo 2015; (67(11)):1359-69 doi:10.11477/mf.1416200306.

    PMID: 26560951
  2. 2

    Complication of Hepatitis A Infection: Case Report of Acute Inflammatory Demyelinating Polyneuropathy.

    Laursen D, Krug J, Wolford R

    Clinical practice and cases in emergency medicine 2021; (5(1)):113-116 doi:10.5811/cpcem.2020.9.48827.

    PMID: 33560967
  3. 3

    Study of total duration of distal compound muscle action potential in demyelinating and axonal Guillain-Barre' syndrome.

    Ginanneschi F, Cioncoloni D, Capoccitti G, et al.

    Neurological research 2023; (45(4)):381-389 doi:10.1080/01616412.2022.2148517.

    PMID: 36403142
  4. 4

    Clinical Features Indicating the Need for Mechanical Ventilation in Patients with Guillain Barre Syndrome.

    Umer SR, Nisa Q, Kumari M, et al.

    Cureus 2019; (11(8)):e5520 doi:10.7759/cureus.5520.

    PMID: 31687295
  5. 5

    Clinical features and outcome of Guillain-Barre syndrome in Saudi Arabia: a multicenter, retrospective study.

    Alanazy MH, Bakry SS, Alqahtani A, et al.

    BMC neurology 2021; (21(1)):275 doi:10.1186/s12883-021-02314-5.

    PMID: 34253174
  6. 6

    Differentiating Familial Neuropathies from Guillain-Barré Syndrome.

    Bordini BJ, Monrad P

    Pediatric clinics of North America 2017; (64(1)):231-252 doi:10.1016/j.pcl.2016.08.015.

    PMID: 27894447
  7. 7

    Rate of progression of Guillain-Barré syndrome is not associated with the short-term outcome of the disease.

    Arsenijević M, Berisavac I, Mladenović B, et al.

    Irish journal of medical science 2021; (190(1)):357-361 doi:10.1007/s11845-020-02310-7.

    PMID: 32666503
  8. 8

    Diagnostic criteria and therapeutic implications of rapid-onset demyelinating polyneuropathies.

    Rałowska-Gmoch W, Koszewicz M, Łabuz-Roszak B, et al.

    Experimental and molecular pathology 2024; (140()):104942 doi:10.1016/j.yexmp.2024.104942.

    PMID: 39500252
  9. 9

    [Immune-mediated polyneuropathies].

    Cerezo S, Expósito J, Carrera L, et al.

    Medicina 2025; (85 Suppl 4()):41-46.

    PMID: 41036983
  10. 10

    Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review.

    Savithri Nandeesha S, Kasagga A, Hawrami C, et al.

    Cureus 2024; (16(3)):e57066 doi:10.7759/cureus.57066.

    PMID: 38681292
  11. 11

    [Electrophysiological subtypes and long term prognosis of Guillain-Barré syndrome].

    Zhang J, Song XJ, Hou HQ, et al.

    Zhonghua yi xue za zhi 2016; (96(25)):1987-90 doi:10.3760/cma.j.issn.0376-2491.2016.25.006.

    PMID: 27470955
  12. 12

    Plasma exchange for Guillain-Barré syndrome.

    Chevret S, Hughes RA, Annane D

    The Cochrane database of systematic reviews 2017; (2()):CD001798 doi:10.1002/14651858.CD001798.pub3.

    PMID: 28241090
  13. 13

    Electrophysiological Pattern and Predictors of Functional Outcome of Patients with Guillain Barre Syndrome at a Tertiary Care Hospital in Pakistan.

    Siddiqui M, Majid S, Yusuf H, Mateen F

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2022; (32(3)):364-368 doi:10.29271/jcpsp.2022.03.364.

    PMID: 35148591
  14. 14

    Early electrophysiological study variants and their relationship with clinical presentation and outcomes of patients with Guillain-Barré syndrome.

    Khedr EM, Shehab MM, Mohamed MZ, Mohamed KO

    Scientific reports 2023; (13(1)):14000 doi:10.1038/s41598-023-41072-x.

    PMID: 37634022
  15. 15

    Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.

    Zhang G, Li Q, Zhang R, et al.

    PloS one 2015; (10(7)):e0133520 doi:10.1371/journal.pone.0133520.

    PMID: 26200903
  16. 16

    Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.

    Neurology 2024; (103(9)):e209968 doi:10.1212/WNL.0000000000209968.

    PMID: 39348619

This page is for educational purposes only and does not replace professional medical advice. Always consult your neurologist or healthcare team regarding your specific AIDP diagnosis, symptoms, and treatment plan.

Get notified when new evidence is published on Acute inflammatory demyelinating polyradiculoneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.